Results 1 to 10 of about 303,717 (280)

Repurposing Interleukin-6 Inhibitors to Combat COVID-19 [PDF]

Journal of Immunotherapy and Precision Oncology, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Shumei Kato, Razelle Kurzrock
doaj   +8 more sources

New treatment for antibody-mediated rejection: interleukin-6 inhibitors [PDF]

Clinical Transplantation and Research
Following kidney transplantation, antibody-mediated rejection (AMR) occurs when the antibodies of the immune system attack the transplanted organ, leading to damage of the kidney tissue. De novo human leukocyte antigen donor-specific antibodies (HLA-DSAs)
Byung Hwa Park, Ye Na Kim, Ho Sik Shin
doaj   +5 more sources

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? [PDF]

Atherosclerosis Plus, 2023
Background and aims: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk.
Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis   +6 more
doaj   +6 more sources

Femoral bone mineral density as a tool of personalized medicine for rheumatoid arthritis: Interleukin-6 inhibitors for patients with low density whereas tumor necrosis factor inhibitor for patients with preserved density? [PDF]

SAGE Open Medicine
Objectives: There is a lack of indicators to distinguish between interleukin-6 inhibitors responders and tumor necrosis factor inhibitors responders in the treatment of rheumatoid arthritis.
Hirokazu Takaoka, Tomohiro Miyamura, Kota Shimada   +2 more
doaj   +3 more sources

Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review [PDF]

Frontiers in Pharmacology, 2022
Sepsis is a syndrome with high mortality, which seriously threatens human health. During the pandemic of coronavirus disease 2019 (COVID-19), some severe and critically ill COVID-19 patients with multiple organ dysfunction developed characteristics ...
Ying Wang, Kun Zhu, Rulin Dai, Rui Li, Miao Li, Xin Lv, Qian Yu   +6 more
doaj   +4 more sources

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

Therapeutics and Clinical Risk Management, 2008
Stephanie Hennigan, Arthur KavanaughDivision of Rheumatology, Allergy, Immunology, The University of California, San Diego, CA, USAAbstract: Recent developments in understanding the immunopathogenesis of rheumatoid arthritis (RA), combined with progress ...
Stephanie Hennigan, Arthur Kavanaugh
doaj   +7 more sources

Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways [PDF]

Pharmacology Research & Perspectives
Rheumatoid arthritis (RA) is an autoimmune systemic disease in which pain remains a major and often refractory symptom even after clinical remission of the disease.
Andrej Belančić, Seher Sener, Almir Fajkić, Ines Potočnjak, Mirjana Stanić Benić, Marijana Vučković, Yusuf Ziya Sener, Marija Rogoznica Pavlović, Antonio Markotić, Josipa Radić, Mislav Radić   +10 more
doaj   +2 more sources

A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors

Современная ревматология, 2019
The basis of the clinical picture of adult-onset Still's disease is a triad of symptoms, includingfever, arthralgia/arthritis, and characteristic rash called «Still rash».
R. R. Samigullina, E. A. Vasilenko, V. I. Mazurov   +2 more
doaj   +3 more sources

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge [PDF]

International Journal of Infectious Diseases, 2020
Objective: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19).
Pranay Sinha, Anahita Mostaghim, Catherine G. Bielick, Angela McLaughlin, Davidson H. Hamer, Lee M. Wetzler, Nahid Bhadelia, Maura A. Fagan, Benjamin P. Linas, Sabrina A. Assoumou, Michael H. Ieong, Nina H. Lin, Ellen R. Cooper, Karrine D. Brade, Laura F. White, Tamar F. Barlam, Manish Sagar   +16 more
doaj   +2 more sources

Interleukin-1β promotes interleulin-6 expression via ERK1/2 signaling pathway in canine dermal fibroblasts.

PLoS ONE, 2019
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in the regulation of the immune response and inflammation. In this study, we investigated effect of the proinflammatory cytokine interleukin-1β (IL-1β) on IL-6 expression in canine dermal ...
Nanako Kitanaka, Rei Nakano, Kanae Sugiura, Taku Kitanaka, Shinichi Namba, Tadayoshi Konno, Tomohiro Nakayama, Hiroshi Sugiya   +7 more
doaj   +2 more sources